In comparison to hormone receptor positive (HR+) breast cancer, TNBC is known to have higher levels of PD-L1 expression, with a median PD-L1 CPS of 7.5 and 50% expressing ≥ CPS 10 [30]. This evidence concerns the gene NR4A1 and breast carcinoma.